|Mark A. Socinski, MD|
Professor of Medicine and Thoracic Surgery
Director, Lung Cancer Section, Division of Hematology/Oncology
Clinical Associate Director, Lung SPORE
Co-Director, UPMC Lung Cancer Center of Excellence
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh
UPMC Cancer Pavilion
Dr. Mark A. Socinski is Professor of Medicine and Thoracic Surgery and Director of the Lung Cancer Section, Division of Hematology/Oncology at the University of Pittsburgh in Pittsburgh, Pennsylvania. Board certified in internal medicine and medical oncology, he also is Co-Director of the University of Pittsburgh Medical Center’s Lung Cancer Center of Excellence and the Lung and Thoracic Malignancies Program and the Clinical Associate Director of the Specialized Program of Research Excellence (SPORE) in Lung Cancer. Dr. Socinski is a member of several professional organizations including the American College of Physicians, the American Society of Clinical Oncology, Cancer and Leukemia Group B, the International Association for the Study of Lung Cancer, and the American College of Chest Physicians. He has authored many manuscripts principally in thoracic oncology.
Dr. Socinski received a Master of Science degree in Pathology and a Doctor of Medicine degree from the University of Vermont in Burlington. He completed an internal medicine internship and residency at Harvard Medical School Beth Israel Hospital in Boston. He went on to complete medical oncology and clinical medicine fellowships at the Dana-Farber Cancer Institute.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The presenting faculty members have all made the proper disclosures, and the following relationships are relevant:
Mark A. Socinski, MD, reported a financial interest/relationship or affiliation in the form ofSpeakers’ bureau: Celgene Corporation; Genentech, Inc.; Contracted research: Bristol-Myers Squibb Company; Celgene Corporation; Clovis Oncology; GlaxoSmithKline; Pfizer, Inc.; PUMA Biotechnology; Synta Pharmaceuticals Corp.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS; Deborah Middleton, MS; and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.